神经系统:Multi-Facet治疗目标。

文章的细节

引用
复制到剪贴板

Kaur R, Ambwani SR,辛格

神经系统:Multi-Facet治疗目标。

咕咕叫中国新药杂志。2016;11 (2):110 - 7。

PubMed ID
27086601 (在PubMed
]
文摘

大麻也俗称大麻。培养和使用的许多世纪以来人娱乐和药用用途。湾的大麻类是研究了很长时间,不能充分利用其治疗价值由于其法律地位在大多数国家禁止毒品。研究药物作用于神经系统有许多起伏在最近的过去。目前,众所周知,内源性大麻素在许多障碍的病理作用,他们也在许多医疗条件“保护作用”。一些疾病,如呕吐、疼痛、炎症、多发性硬化症、厌食、癫痫、青光眼、精神分裂症、心血管疾病、癌症、肥胖、代谢综合征相关疾病、帕金森氏症、亨廷顿氏舞蹈症,阿尔茨海默病和妥瑞氏综合征可能通过药物治疗调节神经系统。目前,大麻素受体受体激动剂nabilone和dronabinol用于减少化疗诱导呕吐。新药Sativex(大麻二酚和THC组合)批准在英国,西班牙和新西兰由于多发性硬化症治疗痉挛状态。在我们这对癌症疼痛正在调查中,另一种药物Epidiolex(大麻二酚)也在我们正在调查儿童癫痫发作。利莫那班,CB1受体拮抗剂似乎是一种很有前途的抗肥胖药物在临床试验中也表现出显著的精神副作用。 Due to which the US Food and Drug Administration did not approve Rimonabant in US. It sale was also suspended across the EU in 2008. Recent discontinuation of clinical trial related to FAAH inhibitor due to occurrence of serious adverse events in the participating subjects could be discouraging for the research fraternity. Despite some mishaps in clinical trials related to drugs acting on endocannabinoid system, still lot of research is being carried out to explore and establish the therapeutic targets for both cannabinoid receptor agonists and antagonists. One challenge is to develop drugs that target only cannabinoid receptors in a particular tissue and another is to invent drugs that act selectively on cannabinoid receptors located outside the blood brain barrier. Besides this, development of the suitable dosage forms with maximum efficacy and minimum adverse effects is also warranted. Another angle to be introspected for therapeutic abilities of this group of drugs is non-CB1 and non-CB2 receptor targets for cannabinoids. In order to successfully exploit the therapeutic potential of endocannabinoid system, it is imperative to further characterize the endocannabinoid system in terms of identification of the exact cellular location of cannabinoid receptors and their role as "protective" and "disease inducing substance", time-dependent changes in the expression of cannabinoid receptors.

beplay体育安全吗DrugBank数据引用了这篇文章

药物